Lorediplon

Drug Profile

Lorediplon

Alternative Names: GF-015535-00

Latest Information Update: 23 Dec 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Ferrer
  • Developer Ergomed; Ferrer
  • Class 2 ring heterocyclic compounds; Acetamides; Anxiolytics; Hypnosedatives; Small molecules; Thiophenes
  • Mechanism of Action GABA A receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Insomnia

Most Recent Events

  • 23 Aug 2016 Ferrer completes a phase II trial in Insomnia in Croatia and Poland (PO) (EudraCT2014-001966-87)
  • 04 Feb 2014 Ferrer & Ergomed Clinical Research agree to collaborate on the phase IIa trial of lorediplon for Insomnia
  • 04 Feb 2014 Lorediplon licensed to Ildong Pharmaceuticals in South Korea, Japan & China
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top